Zimbabwe has declined a significant American healthcare agreement worth 367 million US dollars (£272m) over five years over the United States' insistence on sensitive data.
The decision came to light after a internal memorandum from December was leaked, indicating that President Emmerson Mnangagwa deemed the arrangement was "lopsided".
An official representative has since stated that the US was seeking genetic material for scientific study and commercial gain but was unwilling to share the resulting advantages from future treatments.
"We will now turn to the challenging and unfortunate task of scaling back our support in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had furnished over $1.9bn for health programmes to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has called for continued talks to secure a deal agreeable to all parties so the nation's critical HIV programme can continue.
Wider Context
Zimbabwe's decision follows a similar situation in Kenya, where a high court halted a similar health funding agreement following legal challenges were raised about the safety of Kenyans' health data.
After returning to office recently, US President Donald Trump has slashed overseas assistance and shut down the key foreign aid agency.
The agency had overseen aid for the American government, but Trump stated its spending was "inefficient" and his government was seeking government-to-government deals to boost openness and responsibility.
As per reports, Sixteen nations in Africa have to date agreed to these new health pacts, representing more than $18.3bn of fresh investment.
Specifics of the Rejected Agreement
The funds for Zimbabwe was intended to funded "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this collaboration could have provided extraordinary advantages for Zimbabwean communities, particularly the 1.2 million presently receiving HIV treatment through US-supported initiatives," the Ambassador added.
However, government spokesperson Nick Mangwana maintained the proposed deal was "asymmetrical".
"The proposal required Zimbabwe to share its biological resources and data over an extended period, with no equivalent guarantee of access to any medical innovations – such as new medicines or tests – that could be developed from that shared data," Mangwana explained.
"In essence, our nation would provide the basic resources for scientific discovery with no certainty that the end products would be available to our citizens if a future pandemic arise."
National Interest and International Frameworks
He also pointed out that the American exit from the World Health Organization (WHO) and its pursuit of bilateral health agreements were upending structures previously established through the international health agency.
Mangwana cited its Pathogen Access and Benefit Sharing system designed to deal with potential global health emergencies.
"This mechanism is designed to guarantee that when a nation contributes its samples, the benefits – such as medicines and cures – are distributed fairly, not monopolised exclusively by those with the resources to develop them."
These objections over the US deal "are not meant as opposition to America," he added.
"We are open to ongoing dialogue with our American counterparts on how subsequent co-operation might be arranged in a manner that honours the independence and interests of each country."
Health Experts Response
A leading public health body expressed it recognised the official position, but recommended that talks need to persist considering a large portion of the country's Aids initiatives depended on international support.
"If specific concerns exist, including those involving information security or agreement terms, these can frequently be addressed through detailed discussion and mutually agreed protections," the group added.
The situation underscores the complex tensions between receiving vital foreign assistance and safeguarding local interests in an increasingly data-driven world.